Modulation of estrogen receptor α levels by endogenous and exogenous ligands

P. La Rosa, M. Marino, F. Acconcia*

Department of Biology, University Roma Tre, Viale Guglielmo Marconi, 446, I-00146, Rome, Italy
*acconcia@uniroma3.it

KEY WORDS: 17β-estradiol, estrogen receptor, turnover, polyphenols, endocrine disruptors

Abstract

ERα is a ligand-activated transcription factor, member of the nuclear receptor superfamily. Regulation of ERα levels is intrinsically required for its transcriptional activity and thus for the modulation of the physiological actions of the cognate hormone 17β-estradiol (E2). Indeed, ERs exogenous ligands that target this molecular circuitry are used as drugs in clinical practice. Interestingly, some natural and synthetic molecules, which human beings are commonly exposed to, interfere with the endocrine system and operate through ERs by selectively modifying its signalling. In addition, these molecules may also modulate ERα cellular content. Here, we report the recent advances in our understanding of how exogenous ERα ligands impact on receptor levels and change the physiological E2-dependent modulation of specific cellular function.

Introduction

The Estrogen receptors (i.e., ERα and ERβ) are present from lower chordates to mammals and exert their functions by mediating developmental and physiological responses to estrogens and, in particular, to 17β-estradiol (E2) both in males and females. In addition to these physiological roles, the ERs are known to play a prominent role in the development and in the progression of several diseases including different kind of cancers (e.g., breast and endometrial cancer) [1].

The ERs belong to the nuclear receptor protein superfamily, share a well conserved structure at six functional domains (A to F domains) with the C region being the DNA binding domain (DBD) and the E region being the ligand binding domain (LBD) and work as ligand activated transcription factors [1].

The regulation of gene expression occurs through the ERα recruitment to the target genes and follows two distinct pathways. In the direct genomic pathway, ERα recognizes and binds directly to the estrogen responsive element (ERE) located in the promoter of the E2-target genes. On the contrary, in the indirect genomic pathway, the ERα regulates the gene expression of those genes which do not contain the ERE sequence by associating with other transcription factors (e.g., Sp1 and AP-1). Irrespective of whether the mechanism of gene modulation is direct or indirect, ERα interacts with a complex of proteins, which can work as co-activators or co-repressors thus forming a scaffolding structure for other proteins required for productive gene transcription [1].

Beside these two mechanisms, ERα triggers rapid (i.e., seconds to minutes) responses to E2, which are mediated by a pool of the ERα located at the plasma membrane. These fast E2 effects (i.e., non-genomic mechanism) are independent on ERs transcriptional activity and consist in the activation of several signalling cascades (e.g., PI3K/AKT pathway). Functionally, these rapid pathways are necessary and sufficient for the E2-dependent cellular responses related to cell proliferation, survival and apoptosis [1].

Regulation of ERα levels by the endogenous ligand E2

As for other hormone receptors, E2-induced ERα degradation represents a crucial step in coordinating ERs signalling. In particular, the binding of E2 to the receptor drastically lowers the protein half-life from more than 5 hours to less than 2 hours. As many other short-lived proteins, the major mechanism that regulates ERs degradation is the ubiquitin-proteasome pathway. The ERα is addressed to the proteasome because of the action of protein ligases, which polyubiquitinate the ERα. Interestingly, ERα proteasome-mediated degradation also occurs in the absence of E2 and is required for maintaining the physiological steady-state of the receptor [2, 3].

Nonetheless, signalling regulation of the ERα turnover is not fully understood and still needs to be clarified. Indeed, there are many evidences that ERα phosphorylation plays a major role in receptor degradation. This modification, which depends on the E2-evoked activation of the rapid phosphorylation cascades (see above) and is required
for receptor activation, could be a signal for receptor ubiquitination. Degradation of ERα could then follow a cyclic pattern in which the receptor, which becomes phosphorylated after E2 binding, binds DNA, then is ubiquinated and finally degraded by the proteasome [2].

**Modification of ERα cellular levels by exogenous ligands**

From a physiological point of view, the regulation of the ERα cellular levels by E2 functions not only as a mechanism to limit the cellular response to the hormone but also as a mean to allow cells to efficiently respond to the environmental E2 fluctuations, thus synchronizing gene transcription [2, 3]. It is therefore not surprising that deregulation of this negative feedback circuitry contributes to the progression of ERα-positive tumours. Indeed, drugs (e.g., fulvestrant and tamoxifen) that interfere with the ERα stability are used as therapeutic tools [4].

Interestingly, our research group has recently demonstrated that diverse natural and synthetic exogenous ERα ligands can differentially modulate receptor activities, thus working as 'mechanism-specific ligands' [5]. In particular, naringenin (Nar), a flavone found in citrus fruit and in grape juice, affects ERα signalling by decoupling the genomic mechanisms from the rapid ones [5]. On the contrary, the synthetic molecule bisphenol A (BPA) mimics E2 in activating ERα signalling [6]. Therefore, in principle, it is possible that these polyphenols could also affect ERα cellular levels.

Furthermore, since it is well known that such exogenous ligands act also as endocrine disruptors, it is critical to understand how the exogenous ligand-dependent modulation of the ERα cellular levels could affect the cellular behaviour per se as well as in response to the endogenous ERα ligand E2. Preliminary results indicate that acute treatment (0-24 hours) of ducal carcinoma cells (MCF-7) with Nar does not trigger ERα breakdown whereas acute treatment with BPA mimics E2 in inducing receptor degradation. On the contrary, chronic exposure (48 hours) of MCF-7 cells to Nar or BPA results in an increased ERα cellular content with respect to the one observed under E2 treatment. Interestingly, the different Nar- and BPA-dependent modulation of ERα cellular levels appears to be due to the differential ability of these two molecules to inhibit (Nar) or activate (BPA) the proteasome-degradation pathway. Nonetheless, whether Nar or BPA impact on ERα cellular content by modulating the receptor mRNA levels can not be excluded and is currently under investigation.

Remarkably, administration of Nar and BPA either before or after E2 treatment also results in an increase in the ERα cellular levels when compared to the E2 treatment alone. These evidence indicate that exposure to endocrine disruptors drastically modifies the ERα cellular content and possibly the cell response to E2 may diverge from the physiological one.

**Discussion**

The regulation of ERα levels is a process not completely understood. However, it is critical for ERα transcriptional activity and plays a key role in E2 signalling and thus for E2-mediated cellular functions. Therefore, ERα cellular content is finely controlled both at transcriptional and post-transcriptional level [7]. The importance of this molecular circuitry is further witnessed by the fact that some ERα binding molecules, which affect receptor turnover, are also used as drugs in clinical practise [8].

Remarkably, some natural and synthetic molecules, which human beings are commonly exposed to, interfere with the endocrine system and operate through the ERα and ERβ by selectively modifying the ER signalling and the cellular outcomes [5]. Our preliminary evidence indicate that these substances (i.e., Nar and BPA) act by affecting the ERα turnover and possibly ERα mRNA levels. As a consequence, the exogenous ligand-induced modification of the ERα cellular content may result in a different response to cognate hormone E2. Moreover, whether exogenous ligands affect also the regulation of ERβ cellular content still remains to be evaluated and requires intense investigation. Nonetheless, understanding how exogenous ERα and ERβ ligands impact on receptor levels and change the physiological E2-dependent modulation of specific cellular functions is a critical issue given the importance of the ERα and ERβ signalling in several physiological processes and in turn in many hormone-related pathologies (e.g., breast and colon cancers).

**References**


